JP2022511800A - 痛風または高尿酸血症を処置または予防するための化合物の結晶形態 - Google Patents

痛風または高尿酸血症を処置または予防するための化合物の結晶形態 Download PDF

Info

Publication number
JP2022511800A
JP2022511800A JP2021531047A JP2021531047A JP2022511800A JP 2022511800 A JP2022511800 A JP 2022511800A JP 2021531047 A JP2021531047 A JP 2021531047A JP 2021531047 A JP2021531047 A JP 2021531047A JP 2022511800 A JP2022511800 A JP 2022511800A
Authority
JP
Japan
Prior art keywords
theta
crystal
compound
crystal morphology
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021531047A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511800A5 (https=
Inventor
イェン，シュンチー
イェー，リテイン
ジェーン リー，ジョン
ワン，ルイピン
Original Assignee
アースローシ セラピューティクス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アースローシ セラピューティクス，インク． filed Critical アースローシ セラピューティクス，インク．
Publication of JP2022511800A publication Critical patent/JP2022511800A/ja
Publication of JP2022511800A5 publication Critical patent/JP2022511800A5/ja
Priority to JP2024188449A priority Critical patent/JP2025026857A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021531047A 2018-12-06 2019-12-05 痛風または高尿酸血症を処置または予防するための化合物の結晶形態 Pending JP2022511800A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024188449A JP2025026857A (ja) 2018-12-06 2024-10-25 痛風または高尿酸血症を処置または予防するための化合物の結晶形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018119567 2018-12-06
CNPCT/CN2018/119567 2018-12-06
PCT/US2019/064784 WO2020118113A1 (en) 2018-12-06 2019-12-05 Crystalline forms of a compound for treating or preventing gout or hyperuricemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024188449A Division JP2025026857A (ja) 2018-12-06 2024-10-25 痛風または高尿酸血症を処置または予防するための化合物の結晶形態

Publications (2)

Publication Number Publication Date
JP2022511800A true JP2022511800A (ja) 2022-02-01
JP2022511800A5 JP2022511800A5 (https=) 2022-12-12

Family

ID=70974392

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021531047A Pending JP2022511800A (ja) 2018-12-06 2019-12-05 痛風または高尿酸血症を処置または予防するための化合物の結晶形態
JP2024188449A Pending JP2025026857A (ja) 2018-12-06 2024-10-25 痛風または高尿酸血症を処置または予防するための化合物の結晶形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024188449A Pending JP2025026857A (ja) 2018-12-06 2024-10-25 痛風または高尿酸血症を処置または予防するための化合物の結晶形態

Country Status (12)

Country Link
US (2) US12145917B2 (https=)
EP (1) EP3890723A4 (https=)
JP (2) JP2022511800A (https=)
KR (1) KR102946486B1 (https=)
CN (1) CN113226302B (https=)
AU (1) AU2019394974B2 (https=)
BR (1) BR112021010708A2 (https=)
EA (1) EA202191545A1 (https=)
IL (1) IL283663B2 (https=)
SG (1) SG11202105745UA (https=)
TW (1) TWI828817B (https=)
WO (1) WO2020118113A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016105499A1 (en) 2014-12-23 2016-06-30 Intellectual Property Associates, Llc Methods and formulations for transdermal administration
CN113214198B (zh) 2016-07-18 2022-12-23 广州瑞安博医药科技有限公司 用于治疗或预防与痛风或高尿酸血症相关的症状的化合物、组合物和方法
EP3681479B1 (en) 2017-09-15 2024-01-31 Dyve Biosciences, Inc. Sodium bicarbonate for use in the treatment of gout and related disorders
CA3121624A1 (en) 2018-12-06 2020-06-11 Arthrosi Therapeutics, Inc. Methods for treating or preventing gout or hyperuricemia
US12145917B2 (en) 2018-12-06 2024-11-19 Arthrosi Therapeutics, Inc. Crystalline forms of a compound for treating or preventing gout or hyperuricemia
EP3968989A4 (en) * 2019-05-14 2022-12-28 Arthrosi Therapeutics, Inc. COMPOUND FOR TREATMENT OF GOUT OR HYPERURICEMIA
WO2021252630A1 (en) * 2020-06-10 2021-12-16 Arthrosi Therapeutics, Inc. Methods for treating or preventing chronic kidney disease
US20250066316A1 (en) * 2021-12-02 2025-02-27 Arthrosi Therapeutics, Inc. Crystalline forms of a compound for treating or preventing gout or hyperuricemia
CN118974028A (zh) * 2021-12-30 2024-11-15 广州瑞安博医药科技有限公司 用于治疗痛风或高尿酸血症的化合物的制备

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130225673A1 (en) * 2010-10-06 2013-08-29 J-Pharma Co., Ltd. Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
CN104262305A (zh) * 2014-09-16 2015-01-07 东北制药集团股份有限公司 一种苯溴马隆晶型a及其制备方法
CN104311516A (zh) * 2014-09-16 2015-01-28 东北制药集团股份有限公司 一种苯溴马隆晶型b及其制备方法
WO2018017368A1 (en) * 2016-07-18 2018-01-25 Arthrosi Therapeutics, Llc Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
WO1992018106A1 (fr) 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
HU227530B1 (en) 1991-11-22 2011-07-28 Warner Chilcott Company Delayed-release compositions containing risedronate and process for their production
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
JP2616252B2 (ja) 1992-10-16 1997-06-04 日本新薬株式会社 ワックスマトリックスの製法
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
JPH11505258A (ja) 1995-05-17 1999-05-18 セダーシナイ メディカル センター 小腸における消化および吸収を改善させる脂肪酸を含む組成物
DE19624292A1 (de) 1996-06-18 1998-01-02 Merckle Gmbh Verfahren und Zwischenprodukte zur Herstellung von 1'-Hydroxybenzbromaron
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
EP1767531A4 (en) 2004-06-10 2011-01-05 Torii Pharmaceutical Co Ltd 6-HYDROXYBENZBROMARONE OR SALTING MEDICAL COMPOSITIONS CONTAINING THEREOF
US20080305169A1 (en) 2006-05-26 2008-12-11 Japan Tobacco Inc. Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds
BRPI0809843A2 (pt) 2007-04-26 2014-09-23 Auspex Pharmaceuticals Inc "composto, composição farmacêutica e uso de um composto"
TWI377944B (en) 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
US8791077B2 (en) 2008-05-22 2014-07-29 Astrazeneca Ab Method for treating hyperuricemia employing an SGLT2 inhibitor and composition containing same
JP5325065B2 (ja) 2009-09-30 2013-10-23 株式会社富士薬品 新規フェノール誘導体
IT1400609B1 (it) 2010-05-10 2013-06-14 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e metformina e loro uso.
US20150031768A1 (en) 2011-08-19 2015-01-29 The Trustees Of Princeton University C-halogen bond formation
US9060987B2 (en) * 2011-11-04 2015-06-23 Cymabay Therapeutics, Inc. Methods for treating gout flares
US9962362B2 (en) 2012-03-29 2018-05-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting EYA tyrosine phosphatase
KR20210033067A (ko) * 2012-06-04 2021-03-25 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
WO2014113407A2 (en) 2013-01-16 2014-07-24 Children's Hospital Medical Center Use of small molecule inhibitors targeting eya tyrosine phosphatase
JP2016512817A (ja) 2013-03-15 2016-05-09 ヤンセン ファーマシューティカ エヌ．ベー． 高尿酸血症の治療におけるカナグリフロジンとプロベネシドの組合せ
CN105579037A (zh) 2013-05-31 2016-05-11 武田制药美国有限公司 用黄嘌呤氧化酶抑制剂治疗的方法和含黄嘌呤氧化酶抑制剂的组合物
WO2015134467A1 (en) 2014-03-05 2015-09-11 The Trustees Of Princeton University Methods and compositions for direct radioactive labeling of bio-active molecules and building blocks
MX2017001103A (es) 2014-07-31 2017-04-27 Merck Patent Gmbh Derivados de indolizina que son aplicables a enfermedades neurodegenerativas.
WO2018090921A1 (zh) 2016-11-16 2018-05-24 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
WO2018110887A1 (ko) 2016-12-14 2018-06-21 주식회사 엘지화학 헤테로 고리 화합물 및 이를 포함하는 유기 발광 소자
WO2019195118A1 (en) 2018-04-03 2019-10-10 Children's Hospital Medical Center Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension
WO2019233459A1 (zh) 2018-06-08 2019-12-12 江苏威凯尔医药科技有限公司 人表皮生长因子受体抑制剂及其制备方法和应用
US20210338648A1 (en) 2018-10-01 2021-11-04 Astrazeneca Ab Methods and compositions for reducing serum uric acid
CA3121624A1 (en) 2018-12-06 2020-06-11 Arthrosi Therapeutics, Inc. Methods for treating or preventing gout or hyperuricemia
US12145917B2 (en) 2018-12-06 2024-11-19 Arthrosi Therapeutics, Inc. Crystalline forms of a compound for treating or preventing gout or hyperuricemia
EP3962908A4 (en) 2019-04-25 2022-10-26 Board of Regents, The University of Texas System HETEROCYCLIC INHIBITORS OF TYROSINE KINASE
EP3968989A4 (en) 2019-05-14 2022-12-28 Arthrosi Therapeutics, Inc. COMPOUND FOR TREATMENT OF GOUT OR HYPERURICEMIA
CN112079830B (zh) 2019-06-14 2023-12-22 上海翰森生物医药科技有限公司 含并环类衍生物抑制剂、其制备方法和应用
WO2021252630A1 (en) 2020-06-10 2021-12-16 Arthrosi Therapeutics, Inc. Methods for treating or preventing chronic kidney disease
CN111763215B (zh) 2020-07-21 2021-05-18 成都海博为药业有限公司 一种具有含氮杂环结构的化合物及其制备方法和用途
CN112729156A (zh) 2020-12-24 2021-04-30 上海智能制造功能平台有限公司 一种人体数字化测量装置的数据拼接及系统标定方法
CN114697265A (zh) 2020-12-29 2022-07-01 华为技术服务有限公司 一种报文处理方法及装置
IL310870A (en) 2021-08-24 2024-04-01 Arthrosi Therapeutics Inc Quinazoline compounds for treatment of disease
US20250066316A1 (en) * 2021-12-02 2025-02-27 Arthrosi Therapeutics, Inc. Crystalline forms of a compound for treating or preventing gout or hyperuricemia
CN118974028A (zh) 2021-12-30 2024-11-15 广州瑞安博医药科技有限公司 用于治疗痛风或高尿酸血症的化合物的制备

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130225673A1 (en) * 2010-10-06 2013-08-29 J-Pharma Co., Ltd. Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
CN104262305A (zh) * 2014-09-16 2015-01-07 东北制药集团股份有限公司 一种苯溴马隆晶型a及其制备方法
CN104311516A (zh) * 2014-09-16 2015-01-28 东北制药集团股份有限公司 一种苯溴马隆晶型b及其制备方法
WO2018017368A1 (en) * 2016-07-18 2018-01-25 Arthrosi Therapeutics, Llc Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
川口洋子ら: "医薬品と結晶多形", 生活工学研究, vol. 4, no. 2, JPN6014015069, 2002, pages 310 - 317, ISSN: 0005356912 *
平山令明, 有機化合物結晶作製ハンドブック, JPN6014035600, 2008, pages 17 - 23, ISSN: 0005356911 *
高田則幸: "創薬段階における原薬Formスクリーニングと選択", PHARM STAGE, vol. 6, no. 10, JPN6009053755, 15 January 2007 (2007-01-15), pages 20 - 25, ISSN: 0005356913 *

Also Published As

Publication number Publication date
US20250059150A1 (en) 2025-02-20
IL283663B2 (en) 2025-12-01
US20220024889A1 (en) 2022-01-27
TW202039453A (zh) 2020-11-01
BR112021010708A2 (pt) 2021-08-24
CN113226302B (zh) 2023-08-18
KR20210100677A (ko) 2021-08-17
CN113226302A (zh) 2021-08-06
EA202191545A1 (ru) 2021-10-28
TWI828817B (zh) 2024-01-11
AU2019394974B2 (en) 2025-08-28
IL283663A (en) 2021-07-29
IL283663B1 (en) 2025-08-01
EP3890723A4 (en) 2022-08-03
CA3121913A1 (en) 2020-06-11
JP2025026857A (ja) 2025-02-26
US12145917B2 (en) 2024-11-19
AU2019394974A1 (en) 2021-07-15
WO2020118113A1 (en) 2020-06-11
SG11202105745UA (en) 2021-06-29
KR102946486B1 (ko) 2026-03-31
EP3890723A1 (en) 2021-10-13

Similar Documents

Publication Publication Date Title
TWI828817B (zh) 用於治療或預防痛風或高尿酸血症之化合物晶型
JP7656548B2 (ja) 痛風または高尿酸血症を処置するための化合物
JP7528080B2 (ja) 痛風または高尿酸血症を処置または予防するための方法
WO2023098872A1 (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
JP2025524598A (ja) Ｓ１ｐ受容体モジュレーターの結晶形態
CA3121913C (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
EA043666B1 (ru) Кристаллические формы соединения для лечения или профилактики подагры или гиперурикемии
HK40056574A (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
HK40056574B (zh) 用於治疗或预防痛风或高尿酸血症的化合物的晶型
EA049585B1 (ru) Соединение для лечения подагры или гиперурикемии
HK40056575A (en) Methods for treating or preventing gout or hyperuricemia
HK40060723A (en) Compound for treating gout or hyperuricemia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221202

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20230113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240304

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240626